Regenerative aesthetics, done to a clinical standard.
MISEV-compliant exosomes, PRP, amniotic serums, and GLP-1 / GHK-Cu peptide programs — paired with the delivery devices and staff training that make them repeatable.
Aesthetics has become the largest single-specialty market for regenerative biologics, and also the most exposed to under-characterized product. DRS provides MISEV 2023–compliant exosome preparations, PRP and amniotic tissue from HCT/P-compliant tissue banks, and peptide protocols scoped to what licensed clinics can actually prescribe.
Common indications we support
- Facial rejuvenation (skin quality, texture)
- Post-laser and post-microneedling recovery
- Androgenic and telogen effluvium hair loss
- Acne scarring and post-inflammatory pigmentation
- Body contouring adjunct (GLP-1, tirzepatide)
- Post-procedure wound healing acceleration
Devices, biologics & protocols for this specialty
Lot-level CoAs with size distribution, tetraspanin surface markers, and negative-marker workup.
Exosome productsDelivery devices engineered for topical exosome, PRP, and peptide serum penetration.
Delivery devicesAutologous PRP prep systems used for facial rejuvenation and androgenic alopecia protocols.
PRP kitsPepEdHub — 95+ profiles and 110+ protocols including GHK-Cu, GLP-1, and cosmetic peptides.
Peptide platformPublications relevant to this specialty
Curated evidence from our Publications library that references Regenerative aesthetics, done to a clinical standard.
- Therapeutic peptides · 2026 curationPeptide Therapeutics: The 2026 Evidence Base
Therapeutic peptides are short amino-acid sequences that mimic or modulate the body's own signaling molecules. As of 2026, more than 100 peptide drugs are approved globally and roughly 170 more are in active clinical development, spanning metabolic, oncologic, dermatologic, and regenerative indications.
Why it's relevant: GHK-Cu, GLP-1, and cosmetic peptides matched to aesthetic clinic workflows.
Read the publication - Metabolic peptides · Head-to-head dataGLP-1 & Next-Generation Metabolic Peptides
GLP-1 receptor agonists have moved from adjunct diabetes therapy to first-line treatment for obesity and cardiometabolic risk. The 2026 evidence base now includes head-to-head data across semaglutide, tirzepatide, and the emerging triple agonist retatrutide.
Why it's relevant: Body-contouring adjunct workflows with contraindication screens.
Read the publication - Cell-based biologics · Wharton's jelly, UCBPerinatal Mesenchymal Stem Cell Biologics
Perinatal mesenchymal stem cells — sourced from Wharton's jelly, umbilical cord blood, and placental tissue — are increasingly favored over adult autologous MSCs for immunomodulatory potency and yield. 2026 secretome analyses show 3–10× higher expression of key regenerative cytokines than age-matched adult MSCs.
Why it's relevant: Secretome-rich products for skin quality and post-procedure recovery.
Read the publication - Extracellular vesicles · Standardized reportingExosome Characterization & MISEV 2023 Standards
Exosomes are 30 – 150 nm extracellular vesicles that carry proteins, lipids, and RNA cargo between cells. MISEV 2023 — the third revision of Minimum Information for Studies of Extracellular Vesicles from the International Society for Extracellular Vesicles — is the current global standard for characterization and reporting.
Why it's relevant: Applied topically after microneedling, fractional dermal infusion, or laser.
Read the publication - AI & clinical decision support · 2026 review seriesAI in Clinical Practice: Peptide Protocols & Decision Support
AI-assisted clinical decision support is the fastest-growing area of the DRS library. Peptide protocol generation, contraindication screening, and post-market safety monitoring now sit at the intersection of validated LLM tooling and traditional pharmacovigilance.
Why it's relevant: Contraindication screening and evidence-tiered recommendations.
Read the publication
Frequently asked questions
- What regenerative options do aesthetic practices use most?
- Microneedling with fractional dermal infusion, PRP for skin quality and hair, low-level and high-power laser therapy, and topical exosome or growth-factor serums applied after controlled skin injury.
- How many sessions do skin-quality protocols need?
- Three to six sessions spaced three to four weeks apart is the common template, with maintenance every six to twelve months. Collagen remodeling continues for months after the final session.
- Is downtime significant?
- Most device-based regenerative aesthetic protocols involve 24 to 72 hours of erythema and mild swelling. They are far lower-downtime than ablative resurfacing.
- Can these protocols be combined with injectables?
- Yes, with sequencing rules. We provide staging templates so energy-based and needling treatments do not disrupt recently placed neuromodulators or fillers.
Bring regenerative medicine into your practice.
Talk with our team about biologics, devices, or an AI-powered peptide protocol tailored to your patients.